Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nasopharyngeal carcinomas: an update.

J-P Spano1, P Busson, D Atlan

  • 1Avicenne Hospital, Department of Oncology, 125 rue de Stalingrad, 93000 Bobigny, France. jean-philippe.spano@avc.ap-hop-paris.fr

European Journal of Cancer (Oxford, England : 1990)
|October 3, 2003
PubMed
Summary

Nasopharyngeal carcinoma (NPC) is a distinct head and neck cancer, often linked to Epstein-Barr Virus (EBV). Despite being radiosensitive, advanced NPC frequently recurs or metastasizes, necessitating advanced treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of Kaposi sarcoma in people living with HIV who maintain long-term viral suppression: A prospective case-series.

HIV medicine·2026
Same author

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

ESMO open·2026
Same author

Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

International guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Safety of solid oncology drugs in older patients: a narrative review.

ESMO open·2024

Area of Science:

  • Oncology
  • Epidemiology
  • Virology

Background:

  • Nasopharyngeal carcinoma (NPC) is a distinct head and neck cancer with unique epidemiological and etiological characteristics.
  • Undifferentiated NPC (UCNT), the predominant histological subtype, is particularly prevalent in Southeast Asia and associated with Epstein-Barr Virus (EBV).
  • Despite known radiosensitivity and chemosensitivity, NPC often presents with local recurrence or distant metastases, especially in advanced stages.

Purpose of the Study:

  • To review current knowledge on the epidemiology, biology, prognosis, and management of nasopharyngeal carcinoma.
  • To highlight the challenges in local control and distant metastasis for advanced NPC.
  • To discuss recent advancements in radiation techniques and combined chemoradiotherapy modalities.

Main Methods:

Related Experiment Videos

  • Literature review of epidemiological data.
  • Analysis of biological markers and etiological factors, including EBV association.
  • Evaluation of treatment outcomes from clinical trials focusing on radiotherapy and chemotherapy.

Main Results:

  • NPC exhibits distinct endemic patterns, particularly in Southeast Asia.
  • Epstein-Barr Virus (EBV) is a significant cofactor in NPC development.
  • Conventional radiotherapy alone is often insufficient for achieving adequate local control in advanced NPC, leading to recurrence and metastasis.

Conclusions:

  • Nasopharyngeal carcinoma requires a multidisciplinary approach due to its distinct characteristics and propensity for treatment failure.
  • Advancements in radiation therapy and combined modality treatments are crucial for improving outcomes in advanced NPC.
  • Further research into the biology and treatment of NPC is essential to reduce recurrence and metastasis rates.